# Centre for Drug Design & Discovery (CD3)

> Centre for Drug Design & Discovery (CD3) is a VC fund backing Therapeutics. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Leuven, Belgium
- Total investments: 3
- Last investment: Apr 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.cd3.eu/

Centre for Drug Design & Discovery (CD3) is a VC fund in Leuven focused on Therapeutics and Biotechnology. The Centre for Drug Design and Discovery (CD3) is an investment fund and technology transfer platform aimed at promoting the discovery and development of innovative medicines for all kinds of diseases. CD3 achieves this goal by building further on the enormous pool of basic knowledge, innovation and technology of universities and spin-offcompanies. By providing the necessary expertise and financial resources, CD3 ensures that fundamental biomedical research carried out by universities and small biotech companies is translated into more usable results and promising molecules for new medicines. These new, potential medicines can then be further developed by pharmaceutical companies or form the basis for new spin-off companies. With this work method and philosophy, CD3 bridges the gap between academic innovative research and the pharmaceutical industry.

## Contacts

5 contacts available for Centre for Drug Design & Discovery (CD3). Shizune tracks 3 team members at Centre for Drug Design & Discovery (CD3). Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/centre-for-drug-design-discovery-cd3?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Health Care | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 1 | 33% |
| United States | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Arnaud Marchand | Executive Director Medicinal Chemistry | 0 | https://shizune.co/investors/profile/arnaud-marchand |
| Patrick Chaltin | Managing Director | 0 | https://shizune.co/investors/profile/patrick-chaltin |
| Stefaan Allemeersch | Executive Director Business Development | 0 | https://shizune.co/investors/profile/stefaan-allemeersch |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Endlyz Therapeutics | ndLyz Therapeutics, Inc. is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias. | $17.3M | Seed | Apr 23, 2026 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series B | Jan 25, 2023 |  |
| Rewind Therapeutics | Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy. |  | Series A | Jan 25, 2023 |  |

3 of 3 investments shown.

## Co-investors
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 2 deals together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 2 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 2 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 2 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 2 deals together
- [AbbVie](https://shizune.co/investors/profile/abbvie) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Centre for Drug Design & Discovery (CD3) invest in?

Centre for Drug Design & Discovery (CD3) invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Centre for Drug Design & Discovery (CD3)?

Public channels for Centre for Drug Design & Discovery (CD3) include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Centre for Drug Design & Discovery (CD3)?

The team at Centre for Drug Design & Discovery (CD3) includes Arnaud Marchand (Executive Director Medicinal Chemistry), Patrick Chaltin (Managing Director) and Stefaan Allemeersch (Executive Director Business Development). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co